Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Neumega data

GENIZ (Cambridge, Mass.) announced Phase II results with recombinant human interleukin-11, demonstrating a dose-dependent rise in platelet counts.

Of the

Read the full 203 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE